Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) has earned an average rating of “Buy” from the eighteen brokerages that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $296.1176.
Several equities analysts have issued reports on ASND shares. Morgan Stanley upped their target price on shares of Ascendis Pharma A/S from $256.00 to $275.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Wells Fargo & Company reduced their price target on shares of Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Royal Bank Of Canada boosted their price objective on shares of Ascendis Pharma A/S from $275.00 to $280.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Evercore restated an “outperform” rating and set a $329.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, May 15th. Finally, Bank of America raised their target price on shares of Ascendis Pharma A/S from $262.00 to $292.00 and gave the stock a “buy” rating in a report on Thursday, April 16th.
View Our Latest Analysis on Ascendis Pharma A/S
Insiders Place Their Bets
Institutional Trading of Ascendis Pharma A/S
Several large investors have recently modified their holdings of the company. Advisory Services Network LLC bought a new position in Ascendis Pharma A/S in the third quarter valued at about $26,000. Arax Advisory Partners boosted its position in Ascendis Pharma A/S by 212.2% in the fourth quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 104 shares during the last quarter. Leonteq Securities AG bought a new stake in shares of Ascendis Pharma A/S during the 4th quarter valued at about $36,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Ascendis Pharma A/S during the 4th quarter valued at about $42,000. Finally, Global Retirement Partners LLC increased its position in shares of Ascendis Pharma A/S by 111.9% during the 4th quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 113 shares during the last quarter.
Ascendis Pharma A/S Price Performance
Shares of NASDAQ:ASND opened at $255.41 on Friday. The business has a fifty day moving average price of $246.03 and a 200-day moving average price of $236.34. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.00 and a quick ratio of 0.72. The company has a market capitalization of $15.93 billion, a PE ratio of 29.46 and a beta of 0.39. Ascendis Pharma A/S has a 1-year low of $175.19 and a 1-year high of $282.15.
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $0.11. The firm had revenue of $285.45 million for the quarter, compared to analysts’ expectations of $362.47 million. As a group, equities analysts expect that Ascendis Pharma A/S will post 4.49 EPS for the current fiscal year.
About Ascendis Pharma A/S
Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.
The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.
Further Reading
- Five stocks we like better than Ascendis Pharma A/S
- Albemarle’s Blowout Quarter Shows Why Lithium Still Matters
- Can DICK’S Turn Foot Locker Into a Winner?
- Why Dutch Bros Plunged Despite a Q2 Earnings Beat and Record Revenue
- Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of War
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
